Q32 Bio Inc
QTTB
查看详细走势图
4.240USD
+0.370+9.56%
收盘 02/06, 16:00（美东）报价延迟15分钟
52.17M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+9.56%
5天
+9.28%
1月
+27.33%
6月
+136.87%
今年开始到现在
+27.71%
1年
+34.60%
查看详细走势图
TradingKey Q32 Bio Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Q32 Bio Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名134/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价11.33。中期看，股价处于上升通道。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Q32 Bio Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Q32 Bio Inc亮点
亮点风险
Q32 Bio Inc. is a clinical-stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity in autoimmune and inflammatory diseases. It focuses on developing novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. Bempikibart (ADX-914), its advanced product candidate, is a fully human anti-interleukin-7 receptor alpha (IL-7Rα), an antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 (IL-7), and thymic stromal lymphopoietin (TSLP). It has completed two Phase IIa clinical trials evaluating bempikibart, SIGNAL-AA for the treatment of alopecia areata (AA), and SIGNAL-AD for the treatment of atopic dermatitis (AD). ADX-097, a Phase 2 asset and the lead product candidate from its complement inhibitor platform, is a humanized anti-C3d monoclonal antibody, fusion protein.
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
估值低估
公司最新PE估值-1.25，处于3年历史低位
机构减仓
最新机构持股7.92M股，环比减少36.52%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值321.05K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.79
分析师目标
根据
2
位分析师
买入
评级
11.333
目标均价
+181.92%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Q32 Bio Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Q32 Bio Inc简介
Q32 Bio Inc. is a clinical-stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity in autoimmune and inflammatory diseases. It focuses on developing novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. Bempikibart (ADX-914), its advanced product candidate, is a fully human anti-interleukin-7 receptor alpha (IL-7Rα), an antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 (IL-7), and thymic stromal lymphopoietin (TSLP). It has completed two Phase IIa clinical trials evaluating bempikibart, SIGNAL-AA for the treatment of alopecia areata (AA), and SIGNAL-AD for the treatment of atopic dermatitis (AD). ADX-097, a Phase 2 asset and the lead product candidate from its complement inhibitor platform, is a humanized anti-C3d monoclonal antibody, fusion protein.
公司代码QTTB
公司Q32 Bio Inc
CEOMorrison (Jodie Pope)
网址https://www.q32bio.com/
相关品种
